Alyssa Klopfer, PA
Physician Assistant · Silver Spring, MDNPI 1568193431
Payments from drug & device makers
Across 529 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$3K
- Cequr Corporation$1K
- Insulet Corporation$1K
- Novo Nordisk$966
- Sanofi-aventis U.S. LLC$892
- Amneal Pharmaceuticals LLC$811
- plus $6K from 34 others
What the payments were for
- Food & beverage$14,015100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 148 | $3,420 |
| Cequr Corporation | 4 | $1,104 |
| Insulet Corporation | 19 | $1,030 |
| Novo Nordisk | 46 | $966 |
| Sanofi-aventis U.S. LLC | 32 | $892 |
| Amneal Pharmaceuticals LLC | 38 | $811 |
| Bayer | 24 | $615 |
| Boehringer Ingelheim | 26 | $593 |
| Mannkind Corporation | 27 | $551 |
| Dexcom, Inc. | 9 | $478 |
| Xeris Pharmaceuticals, Inc. | 19 | $409 |
| Abbott | 17 | $326 |
| Corcept Therapeutics | 14 | $325 |
| BETA Bionics, Inc. | 7 | $283 |
| AstraZeneca(2 entities) | 15 | $270 |
| Antares Pharma, Inc. | 10 | $254 |
| AbbVie | 9 | $198 |
| Recordati_rare_diseases_inc. | 9 | $197 |
| Amgen | 10 | $185 |
| Tandem Diabetes Care, Inc. | 2 | $132 |
| Madrigal Pharmaceuticals | 4 | $126 |
| Medtronic | 4 | $120 |
| Novartis | 5 | $105 |
| Embecta Corp. | 3 | $80 |
| Halozyme Inc | 3 | $67 |
| Acerus Pharmaceuticals Corporation | 4 | $61 |
| Tolmar, Inc. | 4 | $59 |
| Sequel Med Tech, LLC | 2 | $56 |
| IBSA Pharma Inc. | 2 | $47 |
| Ascendis Pharma Endocrinology Inc | 2 | $35 |
| Rhythm Pharmaceuticals, Inc. | 2 | $35 |
| Lifescan, Inc. | 1 | $25 |
| GSK | 1 | $25 |
| Amphastar Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Pfizer | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,016 in reported general payments places this provider in the 95th percentile of 2,567 physician assistant providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $252,645 |
| TrulicityDulaglutide | 159 | $240,382 |
| MounjaroTirzepatide | 133 | $164,017 |
| JardianceEmpagliflozin | 85 | $88,891 |
| JanuviaSitagliptin Phosphate | 43 | $46,605 |
| FarxigaDapagliflozin Propanediol | 30 | $42,302 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $24,203 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $21,165 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $20,542 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $18,528 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $15,431 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 18 | $11,810 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $10,021 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,742 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 53 | $5,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $3,420 | $404,399292 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $966 | $264,455173 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $593 | $107,41996 claims |
| AstraZenecaFarxiga | $270 | $42,30230 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $811 | $74539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,567 physician assistant providers in Maryland.
Other physician assistant in Silver Spring
- Garland JamesSilver Spring$86K
- Jeffrey KufelSilver Spring$13K
- Margaret JoyceTowson$220K
- Kara CossisBaltimore$177K
- Michael RitmillerOwings Mills$92K
- Melissa BearekmanBaltimore$81K
- Brittany YerkesSalisbury$81K
- Bruce SmithBaltimore$63K
- Shannon MarriottBaltimore$38K
- Amy CollierTimonium$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.